IRLAB Therapeutics (OMX: IRLAB-A)

Last close As at 04/11/2024

SEK14.10

1.50 (11.90%)

Market capitalisation

SEK653m

Based in Sweden, IRLAB Therapeutics is focused on developing novel drugs for the treatment of neurodegenerative diseases utilising its ISP technology platform. Its two lead assets, mesdopetam and pirepemat, are in late-stage clinical trials for the symptomatic treatment of Parkinson’s disease (PD).

PD is characterised by a triad of cardinal motor symptoms, although non-motor symptoms are as debilitating and remain undertreated. Despite substantial efforts to develop disease-modifying approaches in PD, symptomatic treatment remains the mainstay.

Latest Insights

View More

Healthcare | Update

IRLAB Therapeutics — Progress across the pipeline in Q324

Healthcare | Flash note

IRLAB Therapeutics — IRL757 starts strong in Phase I

IRLAB Therapeutics_resized

Sector

Healthcare

Equity Analyst

Arron Aatkar

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Kristina Torfgård

    CEO

  • Viktor Siewertz

    CFO

Balance Sheet

Forecast net cash (SEKm)

74.2

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 8.9 (18.3) 116.3
Relative 12.5 (17.7) 68.8
52 week high/low SEK19.6/SEK5.9

Financials

IRLAB’s Q324 results highlighted progress across its clinical pipeline. Pirepemat cleared its final safety review and completed patient enrolment in the Phase IIb trial, making way for top-line readouts in Q125. IRL757 also made headway, reporting positive interim data from the first Phase I study and the initiation of a second study in older adults, triggering a US$2.5m (SEK26.6m) milestone payment from MSRD. Mesdopetam reported support from regulators in Germany and Portugal for the planned Phase III design, bolstering upcoming discussions with the EMA. This comes amid efforts by IRLAB towards securing a partner for Phase III, which it aims to launch in 2025. The period also saw two new patents for mesdopetam and pirepemat, extending patent protection to at least 2040. We expect funds at hand and inflows from the latest milestone payment to extend the cash runway into Q225 (Q125 previously), past top-line readouts for pirepemat and IRL757. Our valuation adjusts to SEK92.0/share, from SEK86.2/share.

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (öre) P/E (x) P/CF (x)
2022A 61.3 (108.3) (113.1) (218.0) N/A N/A
2023A 5.7 (176.5) (177.8) (343.0) N/A N/A
2024E 104.0 (108.1) (120.8) (233.0) N/A N/A
2025E 32.5 (164.8) (169.9) (327.0) N/A N/A

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free